Arkolith/Insider Trading/RXDX/Form 4

McKenna Mark C.

Chairman, President & CEO, DirectorPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Mar 17, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.9M
Net Open-Market Flow
-$2.9M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 15, 2023Sell(S)25K$116.14$2.9M55K
Mar 15, 2023Option exercise(M)25K$2.90$73K80K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 15, 2023Option exercise(M)25K—$0284K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-019948) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML